 Home > Biochemistry News > Biotechnology News > It is expected to change the treatment model of first-line lymphoma Roche ADC combination reduces the risk of disease progression by 27%

It is expected to change the treatment model of first-line lymphoma Roche ADC combination reduces the risk of disease progression by 27%

 Last Update: 2021-12-28
 Source: Internet
 Author: User

Tags

new chloe perfume

phentermine drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 14, 2021, Genentech, a Roche subsidiary, announced that the "first-in-class" CD79b-targeted antibody-conjugated drug (ADC) Polivy (polatuzumab vedotin) will be linked to a treatment program called R-CHP It has been used in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL) in Phase 3 clinical trials with positive results

DLBCL is the most common type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of NHL

The CD79b protein is specifically expressed in most B cells, making it a promising target for the development of new therapies

This phase 3 clinical trial evaluated Polivy+rituximab+cyclophosphamide+doxorubicin+prednisone in 879 previously untreated DLBCL patients, compared with rituximab Efficacy, safety and pharmacokinetics of standard treatment of monoclonal antibody + cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP)

The efficacy and safety data of the trial showed that at a median follow-up of 28.

▲Polivy+R-CHP significantly improves the progression-free survival of patients (picture source: reference [2])

Reference materials:

[1] Roche's Polivy Combination Reduced The Risk Of Disease Worsening Or Death By 27% In People With Previously Untreated Aggressive Form Of Lymphoma.

[2] Tilly et al.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.